The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

USANA Health Sciences Inc

NYSE: USNA
Last

(U.S.) $145.50

Today's change-3.42 -2.30%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.
 

USANA Health Sciences Inc

NYSE: USNA
Last

(U.S.) $145.50

Today's change-3.42 -2.30%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

USANA Health Sciences Inc down (U.S.)$3.42

USANA Health Sciences Inc closed sharply lower Friday, dropping (U.S.)$3.42 or 2.30% to (U.S.)$145.50. Shares have lost 4.98% over the last five days, but have gained 41.83% over the last year to date. This security has outperformed the S&P 500 by 97.18% during the last year.

Key company metrics

  • Open(U.S.) $147.92
  • Previous close(U.S.) $148.92
  • High(U.S.) $148.84
  • Low(U.S.) $143.91
  • Bid / Ask-- / --
  • YTD % change+41.83%
  • Volume173,277
  • Average volume (10-day)155,318
  • Average volume (1-month)158,970
  • Average volume (3-month)135,270
  • 52-week range(U.S.) $69.76 to (U.S.) $176.88
  • Beta1.08
  • Trailing P/E22.21×
  • P/E 1 year forward20.55×
  • Forward PEG2.06×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.55
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.85%

Based on its net profit margin of 9.85%, USANA Health Sciences Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:Non-Cyclical Consumer Goods & ServicesIndustry:Personal Products
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJul 04, 201507/04/2015Apr 04, 201504/04/2015Jan 03, 201501/03/2015Sep 27, 201409/27/2014
Revenue233219228192
Total other revenue--------
Total revenue233219228192
Gross profit193181190157
Total cost of revenue40383835
Total operating expense194190195163
Selling / general / administrative154151158128
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income39303329
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax39303229
Income after tax25202119
Income tax, total1310119
Net income25202119
Total adjustments to net income--------
Net income before extra. items25202119
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items25202119
Inc. avail. to common incl. extra. items25202119
Diluted net income25202119
Dilution adjustment0------
Diluted weighted average shares13131313
Diluted EPS excluding extraordinary itemsvalue per share1.921.501.661.47
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.921.501.661.47